SHANGHAI – Beijing's Canbridge Life Sciences Inc. has acquired the greater China rights to Puma Biotechnology Inc.'s Nerlynx (neratinib) as an adjuvant for early stage HER2-positive breast cancer and other HER2 tumors, such as gastric cancer, which is highly prevalent in China.